FILTER
FILTERED INTERVIEW RESULTS
Alan Petro
CEO, NEW VISION PHARMACEUTICALS
"We had a client approach us to work on a rapid Covid test, wanting to produce a single-use vial for at-home testing. It was only six weeks between when we had our initial discussion to when we had produced the product for them."
Lars Schneider
PRESIDENT OF BRENNTAG SPECIALTIES, AMERICAS– BRENNTAG NORTH AMERICA, INC
"Project Brenntag and our supply chain capabilities have certainly supported us, providing a clear focus between our different businesses and specializations to grow in the pharma and life science markets."
Donna LaVoie
PRESIDENT & CEO, LAVOIEHEALTHSCIENCE
"The surge of communication need has increased exponentially as companies recognize the necessity of conveying a differentiated story amid the unprecedented number of financings and IPOs over the last two years."
Lori Hu
MANAGING DIRECTOR, VERTEX VENTURES HC
"The M&A market has been relatively slow over the past year as pharma executives wait on the sidelines for the valuation correction to play out, but I believe that we will see M&A activities increase in this coming year."
James Sapirstein
CHAIRMAN, PRESIDENT AND CEO, FIRST WAVE BIOPHARMA
"I believe that in the near future we will be able to effectively control the Covid virus with therapeutics."
Arda Ural
PARTNER & EY AMERICAS INDUSTRY MARKETS LEADER, HEALTH SCIENCES AND WELLNESS
"Our primary objective is to pivot to areas that our clients are focusing on, such as digitalization, ESG and supply chain management."
Jay Shukla
PRESIDENT AND CEO, NIVAGEN PHARMACEUTICALS, INC.
"Nivagen has excellent connections and market access, and we are always looking to in-license FDA-approved products that leverage our expertise in launching in the US market."
Kendalle O’Connell
PRESIDENT AND COO, MASSBIO
"MassBio remains focused on providing the necessary support to help companies succeed so we can continue to stay the best place in the world for life sciences."
Emer Leahy
PRESIDENT & CEO, PSYCHOGENICS
"The main trait we are looking for in partners is access to interesting chemical libraries where, combining good chemistry with our platforms, we can identify novel treatments for neuropsychiatric disorders."
Chris Garabedian
CHAIRMAN AND CEO, XONTOGENY
"People are realizing that our sector may need to be more discerning in deciding which companies are worthy and mature enough to bring to the public markets."
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
Ontario Mining and Toronto's Global Reach 2024 - Digital Interactive
GBR’s annual Ontario Mining and Toronto’s Global Reach 2024 report draws from over 100 interviews with leading executives from major producers, associations, juniors, consultants, investors, and service providers, to provide an in-depth and holistic view of what is happening now, and more pertinently, what could happen in the years ahead.
GBR’s annual Ontario Mining and Toronto’s Global Reach 2024 report draws from over 100 interviews with leading executives from major producers, associations, juniors, consultants, investors, and service providers, to provide an in-depth and holistic view of what is happening now, and more pertinently, what could happen in the years ahead.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
